blood cancer

FDA approves revolutionary blood cancer treatmentFDA’s approval of a new combination treatment for patients with classical Hodgkin lymphoma (cHL) is the first new advanced treatment for the disease in 40 years
Waldenstrom’s drug shows sustained benefit at 2 yearsIbrutinib, a newly approved drug for Waldenstrom’s Macroglobulinemia, a rare form of lymphoma, continued to control the rare blood cancer, with 95% of patients surviving for 2 years, according to a new study, published in The New England Journal of Medicine.
FDA drug approvals-August 2014FDA actions in brief, complete response, fast-track designation, priority review, orphan drug designations, first-time generic approval
FDA approves drug to treat 3 types of blood cancersFDA approved idelalisib (Zydelig, Gilead Sciences) to treat patients with 3 types of blood cancers.